ExOne Co (NASDAQ:XONE) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 2,144,600 shares, an increase of 5.7% from the May 30th total of 2,029,000 shares. Approximately 22.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 120,300 shares, the short-interest ratio is currently 17.8 days.
Separately, Zacks Investment Research downgraded shares of ZEALAND PHARMA/S from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $10.75.
XONE stock traded down $0.12 during mid-day trading on Monday, reaching $8.18. The company had a trading volume of 51,700 shares, compared to its average volume of 123,508. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.24 and a quick ratio of 1.04. The stock has a market cap of $135.74 million, a P/E ratio of -10.49 and a beta of 3.50. The business has a 50 day moving average of $8.06. ExOne has a 12 month low of $5.73 and a 12 month high of $11.73.
ExOne (NASDAQ:XONE) last issued its earnings results on Thursday, May 9th. The industrial products company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.05. ExOne had a negative net margin of 17.29% and a negative return on equity of 17.85%. The business had revenue of $9.58 million for the quarter, compared to the consensus estimate of $10.90 million. Equities analysts anticipate that ExOne will post -0.23 EPS for the current fiscal year.
In other ExOne news, Director Roger William Thiltgen bought 10,000 shares of ExOne stock in a transaction dated Monday, May 20th. The shares were purchased at an average cost of $8.10 per share, for a total transaction of $81,000.00. Following the acquisition, the director now directly owns 17,600 shares in the company, valued at approximately $142,560. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 32.10% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in shares of ExOne by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 150,377 shares of the industrial products company’s stock valued at $996,000 after buying an additional 4,659 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in ExOne by 34.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 84,105 shares of the industrial products company’s stock worth $557,000 after purchasing an additional 21,529 shares during the last quarter. Menta Capital LLC acquired a new stake in ExOne in the 4th quarter worth approximately $70,000. D. E. Shaw & Co. Inc. acquired a new stake in ExOne in the 4th quarter worth approximately $724,000. Finally, Jane Street Group LLC acquired a new stake in ExOne in the 4th quarter worth approximately $68,000. 30.36% of the stock is owned by hedge funds and other institutional investors.
About ExOne
The ExOne Company develops, manufactures, and markets three-dimensional (3D) printing machines, 3D printed and other products, materials, and services to industrial customers primarily in North America, Europe, and Asia. The company manufactures and sells 3D printing machines that serves direct and indirect applications, including components and tools to produce a component; and offers pre-production collaboration and print products for customers.